Literature DB >> 17690058

Differential stimulant response on attention in children with comorbid anxiety and oppositional defiant disorder.

Helly Goez1, Odea Back-Bennet, Nathanel Zelnik.   

Abstract

Attention-deficit hyperactivity disorder (ADHD) affects 3% to 7% of school-age children. Approximately 30% of the children with ADHD also have comorbid anxiety or oppositional defiant disorder. Methylphenidate is the drug of choice for the medical treatment of such cases. When compared with children with ADHD alone, children with comorbid anxiety or oppositional defiant disorder may show worsening of the global attention score in response to methylphenidate and not only a "reduced response," as reported in previous studies. This study included 1122 children diagnosed as ADHD, of which 174 were diagnosed with comorbid anxiety and 141 with comorbid oppositional defiant disorder. All patients performed the Test of Variables of Attention before and after methylphenidate administration. A normal distribution (Gaussian distribution) of reaction to methylphenidate, as measured by the global ADHD score in children diagnosed as pure ADHD, was found. These findings were in contrast to children with ADHD and comorbid anxiety or oppositional defiant disorder who showed a bimodal distribution and hence represent a distinct population. In both groups with comorbid disorders, there was a larger subgroup in which significant worsening of global ADHD score occurred after methylphenidate administration (P < .05). Children with ADHD and comorbid anxiety or oppositional defiant disorder might represent clinically distinct populations in which inattention is secondary to those disorders; therefore, methylphenidate may be an inappropriate treatment for such children.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17690058     DOI: 10.1177/0883073807303221

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  12 in total

1.  The impact of individual and methodological factors in the variability of response to methylphenidate in ADHD pharmacogenetic studies from four different continents.

Authors:  Guilherme Polanczyk; Stephen V Faraone; Claiton H D Bau; Marcelo M Victor; Katja Becker; Reta Pelz; Jan K Buitelaar; Barbara Franke; Sandra Kooij; Emma van der Meulen; Keun-Ah Cheon; Eric Mick; Diane Purper-Ouakil; Philip Gorwood; Mark A Stein; Edwin H Cook; Luis Augusto Rohde
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-12-05       Impact factor: 3.568

2.  Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial.

Authors:  Daniel F Connor; Robert L Findling; Scott H Kollins; Floyd Sallee; Frank A López; Andrew Lyne; Gerald Tremblay
Journal:  CNS Drugs       Date:  2010-09       Impact factor: 5.749

3.  Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder.

Authors:  Reut Gruber; Ridha Joober; Natalie Grizenko; Bennett L Leventhal; Edwin H Cook; Mark A Stein
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-06       Impact factor: 2.576

4.  Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters?

Authors:  Sheila P Garcia; Julia Guimarães; Juliana F Zampieri; Ana Luiza Martinez; Guilherme Polanczyk; Luis Augusto Rohde
Journal:  J Neural Transm (Vienna)       Date:  2009-04-16       Impact factor: 3.575

5.  The effects of chronic methylphenidate administration on operant test battery performance in juvenile rhesus monkeys.

Authors:  J S Rodriguez; S M Morris; C E Hotchkiss; D R Doerge; R R Allen; D R Mattison; M G Paule
Journal:  Neurotoxicol Teratol       Date:  2009-09-06       Impact factor: 3.763

6.  A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.

Authors:  César Soutullo; Tobias Banaschewski; Michel Lecendreux; Mats Johnson; Alessandro Zuddas; Colleen Anderson; Richard Civil; Nicholas Higgins; Ralph Bloomfield; Liza A Squires; David R Coghill
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

7.  Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia.

Authors:  Pavel Golubchik; Jonathan Sever; Abraham Weizman
Journal:  Int Clin Psychopharmacol       Date:  2014-07       Impact factor: 1.659

8.  Are psychiatric comorbidities and associated cognitive functions related to treatment response to methylphenidate in boys with attention-deficit/hyperactivity disorder?

Authors:  Mandy H Chan; Patrick Wl Leung; Ting-Pong Ho; Se-Fong Hung; Chi-Chiu Lee; Chun-Pan Tang; Ka-Chai Cheung; Fung-Yee Ching; Fefe Hk Chan; Lu-Hua Chen; Merce Garcia-Barcelo; Pak-Chung Sham
Journal:  Neuropsychiatr Dis Treat       Date:  2017-04-11       Impact factor: 2.570

Review 9.  Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit.

Authors:  Tangunu Fosi; Maria T Lax-Pericall; Rod C Scott; Brian G Neville; Sarah E Aylett
Journal:  Epilepsia       Date:  2013-12       Impact factor: 5.864

Review 10.  Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe.

Authors:  Michael Huss; Wai Chen; Andrea G Ludolph
Journal:  Clin Drug Investig       Date:  2016-01       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.